Ethyl Acetate

Ethyl Acetate

SCHEMBL37398

CCOC(=O)CCO.CCOC(C)=O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.64
LMNA P02545 2/20 0.64
HSD17B10 Q99714 2/20 0.64
GAA P10253 2/20 0.54
MGAM O43451 1/20 0.54
SI P14410 1/20 0.54
MGAM2 Q2M2H8 1/20 0.54
CYP4F2 P78329 3/20 0.48
CYP4A11 Q02928 3/20 0.48
CYP1A2 P05177 1/20 0.48
TRPA1 O75762 1/20 0.44
TSHR P16473 3/20 0.41
NR1I2 O75469 1/20 0.39
PGR P06401 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
PTGS2 P35354 1/20 0.39
PDE4D Q08499 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 2/20 0.38
ALOX15 P16050 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL3310615 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL16144857 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL15417972 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL1259377 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL2857167 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL14630991 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL1259419 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL15418012 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL1260460 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM
Ethyl Acetate SCHEMBL3312144 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10GAAMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
CN-118056833-A Barbituric acid macrocyclic compound and preparation method and application thereof 中国科学院化学研究所 2024-05-21 CN disclosed
US-20240158430-A1 NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT AKITA UNIVERSITY (JP) 2024-05-16 US disclosed
US-20240083899-A1 PURINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2024-03-14 US disclosed
WO-2024043319-A1 ANTIBODY-DRUG COMPLEX エーザイ・アール・アンド・ディー・マネジメント株式会社 2024-02-29 WO disclosed
WO-2024013400-A1 AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS OXFORD ANTIBIOTIC GROUP GMBH (AT) 2024-01-18 WO disclosed
CN-116670126-A Azaheteroaryl derivatives with EGFR inhibiting activity, preparation method and application thereof 上海和誉生物医药科技有限公司 2023-08-29 CN disclosed
US-20230190698-A1 BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO., LTD. (JP) 2023-06-22 US disclosed
US-11617733-B2 Bicyclic compound and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2023-04-04 US disclosed
US-11584800-B2 Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-21 US disclosed
EP-0441263-A1 Dye composition for keratinous fibers KAO CORPORATION (JP) 1991-08-14 EP disclosed
US-5021439-A Senile dementia and memory dysfunction TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-06-04 US disclosed
EP-0395244-A1 Pyridine derivatives JOHN WYETH & BROTHER LIMITED (GB) 1990-10-31 EP disclosed
EP-0367393-A2 New heterocyclic compounds, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1990-05-09 EP disclosed
US-4920103-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1990-04-24 US disclosed
EP-0169725-B1 PROSTAGLANDIN ANALOGUES FOR THE TREATMENT OF BRAIN CELLS ANOXIA ONO PHARMACEUTICAL CO., LTD. (JP) 1990-03-21 EP disclosed
US-4812475-A TREATMENT OF OXYGEN DEFICIENCY OF BRAIN ONO PHARMACEUTICAL CO., LTD. (JP) 1989-03-14 US disclosed
EP-0262904-A2 Modifications of mycinose and 3-0-demethylmycinose in tylosintype macrolides ELI LILLY AND COMPANY (US) 1988-04-06 EP disclosed
US-4552841-A N-Acetyl-β-D-glucosaminides for determining N-acetyl-β-D-glucosaminidase activity SHIONOGI & CO., LTD. (JP) 1985-11-12 US disclosed
US-4433139-A N-Acetyl-β-D-glucosamnides for determining N-acetyl-β-D-glucosaminidase activity SHIONOGI & CO., LTD. (JP) 1984-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190698-A1 BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES CYP4A11, PDE3A, GUCY1B1 ALDH1A1 716/4885LMNA 821/4885HSD17B10 628/4885
US-20240158430-A1 NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT STAT3, STAT6, HDAC1 ALDH1A1 490/4885LMNA 4364/4885HSD17B10 1785/4885
US-11617733-B2 Bicyclic compound and use thereof for medical purposes CYP4A11, PDE3A, GUCY1B1 ALDH1A1 716/4885LMNA 821/4885HSD17B10 628/4885
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 ALDH1A1 1628/4885LMNA 3833/4885HSD17B10 3520/4885
US-11584800-B2 Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate ERBB2, EGFR, H1-2 ALDH1A1 1073/4885LMNA 160/4885HSD17B10 2952/4885
US-20240083899-A1 PURINONE DERIVATIVE BTK, KIT, SYK ALDH1A1 492/4885LMNA 3626/4885HSD17B10 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.